Compare Palantir Technologies Inc (PLTR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs TG Therapeutics Inc — how do they compare? Palantir Technologies Inc trades at $169.16 (market cap $409.24B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Palantir Technologies Inc is far larger — about 48× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Palantir Technologies Inc nearer its low. Which is the better fit depends on your goals.
| PLTR | TGTX | |
|---|---|---|
Market Cap | $409.24B | $8.53B |
Sector | Technology | Health |
52-Week High | $207.18 | $59.06 |
52-Week Low | $107.27 | $26.94 |
Enterprise Value | $400.04B | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir Technologies (PLTR) trades at $170.30, down 2.31% on the day but remains in a strong uptrend with recent earnings beats driving momentum. The stock shows robust fundamentals with 93% revenue growth in Q2 2026 and a 49% net income margin, though valuation metrics remain elevated with a P/E of 145.6. Technical indicators are neutral with support at $168 and resistance at $174, while the recent Nebius partnership strengthens Palantir's sovereign AI positioning.
Palantir's outlook remains positive with strong earnings momentum and strategic AI partnerships, though premium valuation and competitive pressures present risks. The consensus price target of $211.38 suggests 24% upside potential, supported by 50% analyst buy ratings. Key risks include valuation sustainability and compute capacity constraints as demand surges.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
